Latest news with #Mongon
Miami Herald
2 days ago
- Business
- Miami Herald
Tylenol-maker Kenvue fires CEO Thibaut Mongon, hires Kirk Pery as interim CEO
July 14 (UPI) -- American consumer health company Kenvue on Monday fired CEO Thibaut Mongon. Kenvue, which produces Aveeno, Band-Aid Brand, Johnson's, Listerine, Neutrogena and Tylenol, announced that Mongon "has departed the company" and stepped down from the board. Kirk Perry, a director with more than 30 years of technology and business transformation experience, was appointed as interim CEO. "As interim CEO, I am excited to leverage my decades of experience leading businesses across the consumer and technology industries and work with the Board and leadership team to put the business on the strongest footing to deliver on Kenvue's full potential and realize our goal of top-tier financial performance," Perry said. Heidrick & Struggles, an executive search firm, is assisting the company in a search for its next fulltime CEO. "The Board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the Company's portfolio and how it operates. At the same time, with the CEO transition and recent appointment of a new CFO, we are aligning leadership expertise to drive the Company forward," said Larry Merlo, Kenvue's Chair of the Board. "We are confident that the steps we are taking put Kenvue on the right path to deliver both near- and long-term value creation for shareholders." Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
2 days ago
- Business
- UPI
Tylenol-maker Kenvue fires CEO Thibaut Mongon, hires Kirk Pery as interim CEO
July 14 (UPI) -- American consumer health company Kenvue on Monday fired CEO Thibaut Mongon. Kenvue, which produces Aveeno, Band-Aid Brand, Johnson's, Listerine, Neutrogena and Tylenol, announced that Mongon "has departed the company" and stepped down from the board. Kirk Perry, a director with more than 30 years of technology and business transformation experience, was appointed as interim CEO. "As interim CEO, I am excited to leverage my decades of experience leading businesses across the consumer and technology industries and work with the Board and leadership team to put the business on the strongest footing to deliver on Kenvue's full potential and realize our goal of top-tier financial performance," Perry said. Heidrick & Struggles, an executive search firm, is assisting the company in a search for its next fulltime CEO. "The Board's strategic review is underway, and we are considering a broad range of potential alternatives, including ways to simplify the Company's portfolio and how it operates. At the same time, with the CEO transition and recent appointment of a new CFO, we are aligning leadership expertise to drive the Company forward," said Larry Merlo, Kenvue's Chair of the Board. "We are confident that the steps we are taking put Kenvue on the right path to deliver both near- and long-term value creation for shareholders."
Yahoo
03-06-2025
- Business
- Yahoo
Kenvue Leads S&P 500 Decliners as CEO Points to Seasonal Demand Challenges
Shares of Kenvue (KVUE) led S&P 500 decliners Tuesday after the consumer health giant's chief executive indicated the firm faces seasonal demand challenges. Speaking at Deutsche Bank's dbAccess Global Consumer Conference, Kenvue CEO Thibaut Mongon highlighted the importance of seasonality for its allergy products, like Benadryl and Zyrtec. "We saw a longer winter, so winter pushed spring into later in Q2," Mongon said, according to a transcript provided by AlphaSense. "So we see that on allergy where we saw a later start to the season, and so far, it's below last year." Mongon also noted similar seasonal troubles for its sun protection brands, like Neutrogena and Aveeno. "In sun, we see more or less the same. Late start to the season year-to-date behind last year, but the season has not really started for recreational sun, and Memorial Day weekend was just a few days ago," Mongon said. "It was not great, as you and I could see. But, again, we are just at the beginning of the season. So it's too early to read the season. It will certainly impact Q2." Kenvue shares were down more than 7% in recent trading. With today's sharp declines, the stock's year-to-date gains stand at less than 3%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
